Please use this identifier to cite or link to this item: https://doi.org/10.1177/1470320313510584
DC FieldValue
dc.titleAliskiren and losartan trial in non-diabetic chronic kidney disease
dc.contributor.authorWoo, Keng-Thye
dc.contributor.authorChoong, Hui-Lin
dc.contributor.authorWong, Kok-Seng
dc.contributor.authorTan, Han-Kim
dc.contributor.authorFoo, Marjorie
dc.contributor.authorFook-Chong, Stephanie
dc.contributor.authorLee, Evan JC
dc.contributor.authorAnantharaman, Vathsala
dc.contributor.authorLee, Grace SL
dc.contributor.authorChan, Choong-Meng
dc.date.accessioned2022-07-28T01:01:18Z
dc.date.available2022-07-28T01:01:18Z
dc.date.issued2014-12-01
dc.identifier.citationWoo, Keng-Thye, Choong, Hui-Lin, Wong, Kok-Seng, Tan, Han-Kim, Foo, Marjorie, Fook-Chong, Stephanie, Lee, Evan JC, Anantharaman, Vathsala, Lee, Grace SL, Chan, Choong-Meng (2014-12-01). Aliskiren and losartan trial in non-diabetic chronic kidney disease. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 15 (4) : 515-522. ScholarBank@NUS Repository. https://doi.org/10.1177/1470320313510584
dc.identifier.issn14703203
dc.identifier.issn17528976
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/229319
dc.description.abstractIntroduction: This is a report of a clinical trial on the therapeutic efficacy and safety of combined aliskiren and losartan (an angiotensin II receptor blocker (ARB)) versus aliskiren alone and ARB alone in non-diabetic chronic kidney disease (CKD) over a 3-year period. Materials and methods: This was a randomised trial in 155 patients with non-diabetic CKD comparing aliskiren (150 mg/day) (n=52) versus losartan (100 mg/day) (n=52) and the third group aliskiren (150 mg/day) combined with losartan (100 mg/day) (n=51). The trial utilised primary renal end points of eGFR <15 ml/min or end-stage renal failure. Results: All three groups had significant reduction of proteinuria (p<0.001 for all). The changes in eGFR, total urinary protein from baseline to each year were not significantly different between the three therapeutic groups. Conclusion: This study in non-diabetic CKD patients showed that combination therapy with aliskiren and ARB was as efficacious as aliskiren alone and ARB alone. There was one patient who developed a non-fatal stroke in the combined aliskiren and ARB group while the other two groups had none.
dc.language.isoen
dc.publisherSAGE PUBLICATIONS LTD
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectPeripheral Vascular Disease
dc.subjectCardiovascular System & Cardiology
dc.subjectAliskiren
dc.subjectchronic kidney disease
dc.subjectproteinuria
dc.subjectside effects
dc.subjectclinical trial
dc.subjectANGIOTENSIN RECEPTOR BLOCKERS
dc.subjectDIRECT RENIN INHIBITOR
dc.subjectEFFICACY
dc.subjectSAFETY
dc.subjectMETAANALYSIS
dc.subjectHYPERTENSION
dc.subjectMANAGEMENT
dc.subjectRAMIPRIL
dc.typeArticle
dc.date.updated2022-07-23T03:13:46Z
dc.contributor.departmentDEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
dc.contributor.departmentDEPT OF MEDICINE
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1177/1470320313510584
dc.description.sourcetitleJOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
dc.description.volume15
dc.description.issue4
dc.description.page515-522
dc.description.placeUNITED KINGDOM
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Aliskiren and Losartan in NonDiabetic Kideny Disease.pdf192.3 kBAdobe PDF

CLOSED

Published

SCOPUSTM   
Citations

9
checked on Nov 25, 2022

Page view(s)

40
checked on Nov 17, 2022

Download(s)

1
checked on Nov 17, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.